ABIO Stock Summary and Trading Ideas (Arca Biopharma | NASDAQ:ABIO)

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Arca Biopharma trades on the NASDAQ stock market under the symbol ABIO.

As of April 19, 2024, ABIO stock price climbed to $3.36 with 596,088 million shares trading.

ABIO has a beta of -0.28, meaning it tends to be less sensitive to market movements. ABIO has a correlation of 0.00 to the broad based SPY ETF.

ABIO has a market cap of $48.72 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ABIO stock traded as high as $3.90 and as low as $1.56.

The top ETF exchange traded funds that ABIO belongs to (by Net Assets): VTI, VXF, DFAT, DFSU.

ABIO has outperformed the market in the last year with a price return of +68.0% while the SPY ETF gained +21.3%. ABIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +108.7% and +9.1%, respectively, while the SPY returned +4.3% and -3.4%, respectively.

ABIO support price is $3.14 and resistance is $3.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABIO stock will trade within this expected range on the day.